Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic Hyperuricemia
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07613138, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Zhecheng Biotechnology Co., Ltd.
- Trial code
- NCT07613138
- Record updated
- 17 June 2026
- Original description
The goal of this clinical trial is to learn whether tart cherry citrate effervescent tablets can lower uric acid levels in people with asymptomatic hyperuricemia (high uric acid levels without gout symptoms).Read full original descriptionShow less
Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic Hyperuricemia: A Study Protocol for a Single-Center, Randomized, Placebo-Controlled Trial
The goal of this clinical trial is to learn whether tart cherry citrate effervescent tablets can lower uric acid levels in people with asymptomatic hyperuricemia (high uric acid levels without gout symptoms).
The main question it aims to answer is:
Does taking tart cherry citrate effervescent tablets lower uric acid levels more effectively than taking a placebo (inactive) tablet, when both groups also receive lifestyle guidance?
Researchers will compare two groups of participants. Both groups will receive lifestyle guidance (advice on diet and exercise). In addition:
* One group will take the tart cherry citrate effervescent tablets. * The other group will take a placebo effervescent tablet (looks and tastes the same but contains no active ingredient).
The study will last 24 weeks.
Participants will:
* Take the assigned effervescent tablet twice daily for 24 weeks * Follow lifestyle guidance for diet and exercise * Attend scheduled clinic visits for checkups and tests * Provide blood and urine samples for testing
Inclusion: Aged 18 to 65 years, regardless of sex; Meet the diagnostic criteria for primary hyperuricemia, with serum urate levels between 420 μmol/L and 540 μmol/L (for those without comorbidities) or between 420 μmol/L and 480 μmol/L (for those with at least one of the following comorbidities: hypertension, dyslipidemia, diabetes mellitus, obesity, stroke, coronary heart disease, heart failure, or CKD stage ≥2); Participants with asymptomatic hyperuricemia who have not previously received urate-lowering therapy and have no history of acute gout flares; Voluntarily participate in the study and provide written informed consent.
Exclusion: Severe cardiac diseases, such as decompensated heart failure (NYHA class III or IV), unstable angina, or a history of myocardial infarction within the previous 12 months; Current use of medications that affect urate levels, including febuxostat, allopurinol, benzbromarone, probenecid, azathioprine, 6-mercaptopurine, cyclosporine, cyclophosphamide, pyrazinamide, sulfamethoxazole, trimethoprim, theophylline, thiazide diuretics, aspirin (>325 mg/day) or other salicylates, losartan, or intravenous colchicine; Participation in another clinical trial within the three months prior to screening; Presence of other concurrent conditions that, in the investigator's judgment, may affect the efficacy evaluation or result in poor compliance; Known allergy to any of the study medications, food products, or their components; current allergies; or known hypersensitivity; Acute infection or active gastrointestinal ulcers; History of thyroid dysfunction; Secondary hyperuricemia due to hematologic disorders, renal diseases, or radiotherapy/chemotherapy for malignancies; Brain disorders with impaired judgment, or mental disorders that preclude cooperation; Malignancy or active tuberculosis; Active liver disease or cirrhosis, or liver dysfunction with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >2 times the upper limit of normal (ULN); Estimated glomerular filtration rate (eGFR) <60 mL/min; Renal cysts, medullary sponge kidney, or other obstructive nephropathies; Rheumatoid arthritis requiring treatment or arthropathies due to other causes; Alcohol or substance abuse; Use of glucocorticoids; Any other reason that, in the investigator's judgment, makes the participant unsuitable for enrollment in this trial.